Gemcitabine in NK/T Cell Lymphoma

We retrospectively review patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen

Completed

Looking for future studies?

Key information

Conditions

NK/T Cell Lymphoma Lymphoma Lymphoma, Extranodal NK-T-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Neoplasms Neoplasms by Histologic Type

Age range

15 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Samsung Medical Center

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

NK/T cell lymphoma
relapse or refractory disease
gemcitabine containing treatment

Exclusion criteria

Treatment and study plan

Primary outcomes

Overall response rate

Time frame: 2012-May

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Official study title

Gemcitabine in Pretreated/Refractory NK/T Cell Lymphoma

Important dates

Study start: 2012
Primary completion: 2013
Study completion: 2013
First posted: Aug 8, 2012
Registry last updated: Feb 13, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting